Loading
Baxter International Inc Stock: price and insider trades · United States
Baxter International Inc: what insiders have been doing
Headquartered in Deerfield, United States, Baxter International Inc belongs to the Healthcare & Pharma sector and traces its origins to 1931. Filings by its managers are published through SEC (Form 4). The last twelve months, up to 18 October 2026, brought 25 filings signed by 12 insiders.
No open-market purchase or sale appears among the filings, only grants, plan transactions and other operations. Because grants and exercises are largely decided by remuneration plans, they are not counted as purchases here.
Over the last twelve months, not one insider purchase of Baxter International Inc stock was filed. Filings reach the SEC (Form 4) feed a median of 4 days after the trade. The legal deadline for a Form 4 is two business days after the transaction.
Compared with its exchange (5,813 companies, median 19 filings), a count of 25 filings is above the norm. The full history, which starts in 2016, counts no purchases against 2 sales. In its latest annual report filed with the SEC (10-K, fiscal year ended 31 December 2025), the company reported revenue of 11.24 bn USD and net income of -957.0 m USD, with a dividend of 0.52 USD per share.
For comparison within the same sector, see the insider buying recorded at Anixa Biosciences Inc and Vivos Inc. This summary is built from SEC (Form 4) disclosures alone and does not predict where the share price will go.
Insider Decl.
223
Thresholds
n/a
Buy Volume
n/a
n/a
Sell Volume
€177,706
2 ops. · all time
Analyst consensus: bullish or bearish?
Analysts rate Baxter International Inc Hold (neutral), based on 12 analysts. Average price target: US$27.92.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Fundamental score
Ranked 21,473 of 24,148 companies
23.3
score / 100
Value27
Quality19
FCF yld2.4%
Earn yld-7.2%
EV/EBITDA30.2x
ROE-14%
Gross mgn30%
Net mgn-8.5%
Debt/EBITDA12.8x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$25.76
Analyst consensus
12 analystsHold
US$20.00Target US$27.92(+8%)US$40.00
Income statement
RevenueUS$11.2B
Gross profitUS$3.4B30% margin
EBITDAUS$766M7% margin
Net income-US$957M-9.3% margin
Valuation
PER (forward)12.6x
P/Book2.1x
Beta0.65
Balance sheet & cash
Market capUS$13.3B
Total debtUS$9.8B
Free Cash FlowUS$323M
Debt / Equity156%
Profitability & ownership
ROE-14.4%
ROA2.8%
% insiders0.3%
% institutions110.4%
Last declaration on 3 September 2026
Declarations223 total
750 shares@ US$25.480.0002% mcap76.1% of flowCommon Stock, $1 par valueSEC:0001628280-26-060479:0
2,098 shares@ US$25.700.0004% mcap100.0% of flowCommon Stock, $1 par valueSEC:0001628280-26-060469:0
54,276 shares@ US$25.700.011% mcap100.0% of flowCommon Stock, $1 par valueSEC:0001628280-26-060476:0
321 shares@ US$18.680.0001% mcap23.9% of flowCommon Stock, $1 par valueSEC:0001628280-26-040214:0
153 shares@ US$18.680.0000% mcap100.0% of flowCommon Stock, $1 par valueSEC:0001628280-26-040222:0
13,426 shares0Common Stock, $1 par valueSEC:0001628280-26-040231:0
1,932 shares@ US$17.69100.0% of flowCommon Stock, $1 par valueSEC:0001628280-26-016420:0
6,620 shares@ US$17.6912.0% of flowCommon Stock, $1 par valueSEC:0001628280-26-016408:0
2,848 shares@ US$17.69100.0% of flowCommon Stock, $1 par valueSEC:0001628280-26-016412:0
12,674 shares@ US$17.6926.2% of flowCommon Stock, $1 par valueSEC:0001628280-26-016405:0
8,153 shares@ US$17.6920.3% of flowCommon Stock, $1 par valueSEC:0001628280-26-016401:0
201,804 shares0Common Stock, $1 par valueSEC:0001628280-26-014248:0
23,742 shares0Common Stock, $1 par valueSEC:0001628280-26-014241:0
26,709 shares0Common Stock, $1 par valueSEC:0001628280-26-014239:0
42,735 shares0Common Stock, $1 par valueSEC:0001628280-26-014236:0
30,864 shares0Common Stock, $1 par valueSEC:0001628280-26-014234:0
1,614 shares@ US$19.693.7% of flowCommon Stock, $1 par valueSEC:0001628280-26-014243:0
17,806 shares0Common Stock, $1 par valueSEC:0001628280-26-014245:0
1,811 shares0Common Stock, $1 par valueSEC:0001628280-26-009023:0
30,504 shares0Common Stock, $1 par valueSEC:0001628280-26-007413:0
2,273 shares0Common Stock, $1 par valueSEC:0001628280-26-007420:0
17,055 shares0Common Stock, $1 par valueSEC:0001628280-26-007418:0
18,951 shares0Common Stock, $1 par valueSEC:0001628280-26-007416:0
650 shares@ US$19.150.2% of flowCommon Stock, $1 par valueSEC:0001628280-25-057326:0
8,288 shares@ US$19.0822.3% of flowCommon Stock, $1 par valueSEC:0001628280-25-054990:0
25 of 223 declarations
About Baxter International Inc
Baxter International Inc. (ticker BAX) is a U.S.-listed medical technology company traded on the NYSE in the United States. For French-, Belgian- and Swiss-based investors, Baxter is best understood as a defensive healthcare name with global exposure to hospitals, acute care settings and clinical infrastructure. Founded in 1931, the company is headquartered in Deerfield, Illinois, and has evolved from a long-established provider of infusion and hospital solutions into a broader medtech platform with meaningful positions in critical care and patient-care delivery.
Baxter’s business is built around products and services used throughout the hospital workflow. Its portfolio includes infusion systems, parenteral nutrition, medication delivery, renal care therapies, emergency care devices, and a growing set of hospital infrastructure and connected-care solutions. Following the Hillrom acquisition, Baxter materially expanded its presence in smart beds, therapeutic surfaces, patient monitoring, and mobility solutions. That move broadened the company’s offering beyond consumables and core hospital supplies, creating a more integrated proposition for healthcare providers.
Read moreShow less
From a competitive standpoint, Baxter holds a significant position among global suppliers of medical devices and hospital equipment. It competes with specialists across infusion therapy, monitoring, surgical and critical-care equipment, and clinical consumables. Its competitive advantages include a large installed base, recurring demand for consumables, deep customer relationships with hospitals, and the ability to bundle equipment, software and service components. This mix supports a business profile that is typically less cyclical than many industrial sectors, although margins and execution remain sensitive to manufacturing, pricing and regulatory discipline.
Geographically, Baxter has a broad international footprint, with meaningful exposure to North America, Europe and other major healthcare markets. The company sells to hospitals, clinics and healthcare systems around the world, which supports scale but also introduces complexity in terms of regulation, supply chain management and product compliance.
Recent developments point to a company in operational transition. In first-quarter 2026, Baxter said it was making progress toward stabilizing the business and reiterated its full-year outlook, while also noting added compliance costs related to European medical-device regulations. Earlier in 2026, Baxter introduced the Dynamo Series smart stretcher for emergency, perioperative and patient-transport use, and announced a strategic partnership with MUSC Health aimed at improving bedside care delivery and addressing nursing challenges. These initiatives reinforce Baxter’s focus on connected care, hospital workflow innovation and operational simplification. For investors, the key themes remain execution, portfolio optimization, regulatory compliance and the company’s ability to convert its broad installed base into steadier growth on the NYSE in the United States.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
